clinical trial · NCT02830477
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Bayer·—·completed·n = 313
Hemophilia A, CongenitalKovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
brief summary
The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose \& dosing frequency, reason for choice of treatment regimen, FVIII product switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data (if performed), KOVALTRY consumption, as well as safety data.
started
Oct 14, 2016
primary completion
Dec 1, 2020
completion
Mar 1, 2021
last updated
Nov 7, 2023
detailed description
Open label, prospective, non-interventional, single arm study in patients receiving KOVALTRY as prophylaxis therapy.
official title
A Multinational Phase IV Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol